Photocure ASA
OSE:PHO
Photocure ASA
Other Items
Photocure ASA
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Other Items
kr12.9m
|
CAGR 3-Years
92%
|
CAGR 5-Years
53%
|
CAGR 10-Years
14%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Other Items
-kr2.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Other Items?
Other Items
12.9m
NOK
Based on the financial report for Dec 31, 2024, Photocure ASA's Other Items amounts to 12.9m NOK.
What is Photocure ASA's Other Items growth rate?
Other Items CAGR 10Y
14%
Over the last year, the Other Items growth was 10%. The average annual Other Items growth rates for Photocure ASA have been 92% over the past three years , 53% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet